Call: 0123456789 | Email: info@example.com

Renfu Pharmaceutical’s turnaround in 2019: sales expenses increased by 10% to nearly 40 billion


Sauna Night News (reporter Li Yunqi) On the evening of April 29, Renfu Pharmaceutical disclosed its 2019 annual report and reported that the company achieved operating income of 21.8 billion yuan, an increase of 31 from the same period last year.700 million, an annual increase of 17.03%; Achieve net profit attributable to shareholders of listed companies8.400 million, successfully turned losses.It is obvious that the sales cost of Renfu Pharmaceutical in 2019 is 39.9.7 billion US dollars, an increase of 10% from 36 trillion in 2018.Renfu Pharmaceutical said that the report continued to strengthen team building, market access, channel expansion, clinical application and other work, and related sales expenses increased as the sales scale increased.In addition, Renfu Pharmaceutical’s annual R & D expenditure in 2019 was 5.90,000 yuan, an increase of 22 from the same period last year.11%. In 2019, the comprehensive gross profit margin of Renfu Pharmaceutical’s main business was 39.49%, of which the business with the highest gross profit margin is the pharmaceutical manufacturing industry, with a gross profit margin of 66.42%.Sauna, Yenet Li Yunqi editor Yue Caizhou proofreading Li Shihui